DNLI
Neutral signalScored 2026-09-05 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Denali Therapeutics Inc.
- Nom
- Denali Therapeutics Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.9B
- Employés
- 503
- PDG
- Ryan J. Watts
- Site web
- https://www.denalitherapeutics.com
- Marché
- ALECAMLXBHVNCGTXIONSNBIX
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 11 439 titres (~261 381,15 $ US)
- Insiders
- Thornberry Nancy
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$187,975
Avg sell (VWAP, 90d window) $23.81 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$79,482 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Chin Peter Scott | Sell · S | 1,654 | $22.29 | $36,868 | Form 4 |
| 2026-09-02 | Thornberry Nancy | Sell · S · 10b5-1 | 615 | $23.74 | $14,600 | Form 4 |
| 2026-09-01 | Schuth Alexander O. | Sell · S · 10b5-1 | 2,768 | $23.44 | $64,882 | Form 4 |
| 2026-08-11 | Schuth Alexander O. | Sell · S | 2,857 | $25.07 | $71,625 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-05 Drivers: fundamentals. Moteurs : fondamentaux.
DNLI presents a mixed picture: strong liquidity (score 85) provides a meaningful cash runway, but the near-total absence of commercial fundamentals (trend score 25) and a pre-revenue, high-burn-rate profile severely…
The first sentence of the analysis written for DNLI on 2026-09-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 9.16 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | -43.9% | -300.5% | -598.3% | |
| Ebitda Margin | 0.0% | 0.0% | -38.9% | -291.0% | -580.7% | |
| Operating Profit Margin | 0.0% | 0.0% | -59.5% | -314.2% | -607.8% | |
| Pretax Profit Margin | 0.0% | 0.0% | -43.9% | -300.5% | -598.3% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -43.9% | -300.6% | -597.2% | |
| Net Profit Margin | 0.0% | 0.0% | -43.9% | -300.6% | -597.2% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -43.9% | -300.6% | -597.2% | |
| Current Ratio | 9.158 | 8.458 | 13.646 | 3.771 | 2.372 | |
| Quick Ratio | 9.158 | 8.458 | 13.646 | 3.771 | 2.372 | |
| Solvency Ratio | -3.797 | -2.864 | -1.045 | -0.755 | -0.638 | |
| Cash Ratio | 2.088 | 1.712 | 1.630 | 0.599 | 0.776 | |
| Price To Earnings Ratio | -5.559 | -7.930 | -20.245 | -10.696 | -18.661 | |
| Price To Earnings Growth Ratio | -0.357 | -0.056 | 0.342 | -1.217 | 0.040 | |
| Forward Price To Earnings Growth Ratio | -0.357 | -0.056 | 0.342 | -1.217 | 0.040 | |
| Price To Earnings Diluted Ratio | -5.559 | -7.930 | -20.245 | -10.696 | -18.661 | |
| Price To Earnings Diluted Growth Ratio | -0.357 | -0.056 | 0.342 | -1.217 | 0.039 | |
| Price To Book Ratio | 2.858 | 2.726 | 2.859 | 3.349 | 5.632 | |
| Price To Sales Ratio | 0.000 | 0.000 | 8.919 | 32.186 | 111.383 | |
| Price To Free Cash Flow Ratio | -6.863 | -9.219 | -7.948 | -13.297 | -24.649 | |
| Price To Operating Cash Flow Ratio | -7.021 | -9.641 | -8.235 | -14.266 | -25.640 | |
| Debt To Assets Ratio | 0.032 | 0.035 | 0.045 | 0.041 | 0.046 | |
| Debt To Equity Ratio | 0.036 | 0.040 | 0.051 | 0.058 | 0.067 | |
| Debt To Capital Ratio | 0.035 | 0.038 | 0.048 | 0.055 | 0.062 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.129 | 1.118 | 1.119 | 1.401 | 1.459 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.331 | 0.142 | 0.050 | |
| Operating Cash Flow Ratio | -4.195 | -3.402 | -4.591 | -0.672 | -0.559 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -1.083 | -2.256 | -4.344 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.023 | 1.046 | 1.036 | 1.073 | 1.040 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -11.225 | -7.138 | -6.853 | -4.055 | -3.303 | |
| Capital Expenditure Coverage Ratio | -43.422 | -21.851 | -27.668 | -13.723 | -24.869 | |
| Dividend Paid And Capex Coverage Ratio | -43.422 | -21.851 | -27.668 | -13.723 | -24.869 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.483 | -6.545 | -22.364 | -10.562 | -18.369 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-60.0% |
| Ebit Margin | 0.0% | 0.0% | ▲188.6% |
| Ebitda Margin | 0.0% | 0.0% | ▲182.1% |
| Operating Profit Margin | 0.0% | 0.0% | ▲196.3% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲188.6% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲188.3% |
| Net Profit Margin | 0.0% | 0.0% | ▲188.3% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲188.3% |
| Current Ratio | 9.158 | ▲0.700 | ▲1.677 |
| Quick Ratio | 9.158 | ▲0.700 | ▲1.677 |
| Solvency Ratio | -3.797 | ▼-0.933 | ▼-1.977 |
| Cash Ratio | 2.088 | ▲0.376 | ▲0.727 |
| Price To Earnings Ratio | -5.559 | ▲2.371 | ▲7.059 |
| Price To Earnings Growth Ratio | -0.357 | ▼-0.301 | ▼-0.107 |
| Forward Price To Earnings Growth Ratio | -0.357 | ▼-0.301 | ▼-0.107 |
| Price To Earnings Diluted Ratio | -5.559 | ▲2.371 | ▲7.059 |
| Price To Earnings Diluted Growth Ratio | -0.357 | ▼-0.301 | ▼-0.107 |
| Price To Book Ratio | 2.857 | ▲0.132 | ▼-0.627 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-30.498 |
| Price To Free Cash Flow Ratio | -6.863 | ▲2.356 | ▲5.532 |
| Price To Operating Cash Flow Ratio | -7.021 | ▲2.620 | ▲5.939 |
| Debt To Assets Ratio | 0.032 | ▼-0.003 | ▼-0.008 |
| Debt To Equity Ratio | 0.036 | ▼-0.003 | ▼-0.014 |
| Debt To Capital Ratio | 0.035 | ▼-0.003 | ▼-0.013 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.129 | ▲0.012 | ▼-0.116 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.105 |
| Operating Cash Flow Ratio | -4.195 | ▼-0.793 | ▼-1.511 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲1.537 |
| Free Cash Flow Operating Cash Flow Ratio | 1.023 | ▼-0.023 | ▼-0.021 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -11.225 | ▼-4.087 | ▼-4.711 |
| Capital Expenditure Coverage Ratio | -43.422 | ▼-21.571 | ▼-17.116 |
| Dividend Paid And Capex Coverage Ratio | -43.422 | ▼-21.571 | ▼-17.116 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.482 | ▲1.062 | ▲7.182 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.90B | $3.35B | $2.95B | $3.49B | $5.42B | |
| Enterprise value | $2.73B | $3.23B | $2.87B | $3.33B | $5.19B | |
| EV / Sales | 0.00x | 0.00x | 8.69x | 30.73x | 106.67x | |
| EV / Op. cash flow | -6.61x | -9.28x | -8.03x | -13.62x | -24.55x | |
| EV / Free cash flow | -6.46x | -8.87x | -7.75x | -12.70x | -23.61x | |
| EV / EBITDA | -5.48x | -6.54x | -22.36x | -10.56x | -18.37x | |
| Net debt / EBITDA | 0.34x | 0.26x | 0.58x | 0.50x | 0.81x | |
| Current ratio | 9.16x | 8.46x | 13.65x | 3.77x | 2.37x | |
| Income quality | 0.81x | 0.82x | 2.46x | 0.75x | 0.73x | |
| Graham net-net | $4 | $4 | $7 | $7 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | |
| Interest burden | 100.0% | 84.2% | 100.0% | 100.0% | 100.0% | |
| Working capital | $802.3M | $762.2M | $986.2M | $1.01B | $519.0M | |
| Invested capital | $922.2M | $887.9M | $1.06B | $1.08B | $588.6M | |
| Return on assets | -44.8% | -30.8% | -12.6% | -22.3% | -20.7% | |
| Operating ROA | -44.1% | -38.6% | -15.0% | -23.8% | -19.7% | |
| Return on tangible assets | -44.8% | -30.8% | -12.6% | -22.3% | -20.7% | |
| Return on equity | -50.6% | -34.4% | -14.1% | -31.3% | -30.2% | |
| Return on invested capital | -52.6% | -38.0% | -18.2% | -30.9% | -28.6% | |
| Return on capital employed | -53.1% | -38.3% | -18.3% | -31.1% | -28.8% | |
| Earnings yield | -17.7% | -12.6% | -4.9% | -9.3% | -5.4% | |
| Free cash flow yield | -14.6% | -10.8% | -12.6% | -7.5% | -4.1% | |
| Capex / Op. cash flow | -2.3% | -4.6% | -3.6% | -7.3% | -4.0% | |
| Capex / Depreciation | 64.2% | 177.0% | 77.4% | 171.8% | 98.9% | |
| Capex / Sales | 0.0% | 0.0% | 3.9% | 16.4% | 17.5% | |
| SG&A / Sales | 0.0% | 0.0% | 31.3% | 83.4% | 162.5% | |
| R&D / Sales | 0.0% | 0.0% | 128.2% | 330.7% | 545.3% | |
| Stock comp / Sales | 0.0% | 0.0% | 32.7% | 92.1% | 175.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 4d | 31d | 9d | |
| Days payables outstanding | 109d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 4d | 31d | 9d | |
| Cash conversion cycle | -109d | 0d | 4d | 31d | 9d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-26 BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,026,413 shares of the company''s stock, valued at approximately $360,759,000. BlackRock Inc. owned about 8.84% of Denali Therapeutics at the end
- 2026-08-20 DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? Denali''s Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
- 2026-08-19 Denali Therapeutics: Bullish On Avlayah And Their Prospects AVLAYAH''s approval has helped validate Denali Therapeutics'' TransportVehicle platform. They''re now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. However, AVLAYAH''s US label limits its near-term potential. Zafinofusp alfa and four TV-enabled 2027 readouts provide meaningful pipeline upside beyond AVLAYAH.
- 2026-08-19 Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA) Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Analyst Recommendations This is a summary of recent recommendations
- 2026-08-13 Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH''s Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI''s TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets.
- 2026-08-10 Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7
- 2026-08-10 Denali Therapeutics Inc. $DNLI Shares Acquired by California State Teachers Retirement System California State Teachers Retirement System increased its position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 25.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 162,576 shares of the company''s stock after acquiring an additional 33,167 shares during the
- 2026-08-07 DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
- 2026-08-07 Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
- 2026-08-06 Denali Therapeutics Q2 Earnings Call Highlights Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer''s disease programs into clinical development.